Skip to main content

Table 1 Demographic, clinical and tumour-related characteristics of patients included in the study (n  =  62)

From: Glyceraldehyde-3-phosphate dehydrogenase is overexpressed in colorectal cancer onset

Age (years)a   69.5 ± 11.4
Gender – n° (%) Male 45 (72.6)
Female 17 (27.4)
Family history of colorectal cancer – n° (%)   10 (16.1)
Fulfillment of revised Bethesda guidelines – n° (%)   14 (22.6)
Tumour location – n° (%) Proximal to splenic flexure 19 (30.6)
Distal to splenic flexure 43 (69.4)
TNM tumour stage – n° (%) I 9 (14.5)
II 21 (33.9)
III 16 (25.8)
IV 16 (25.8)
Tumour size (mm)a   43 ± 20
Differentiation degree – n° (%) Well 6 (9.7)
Moderate 51 (82.2)
Poor 5 (8.1)
Mucinous carcinoma type – n° (%)   10 (16.1)
Mismatch repair deficiency – n° (%)b   4 (6.5)
Synchronous colorectal cancer – n° (%)   5 (8.1)
Synchronous colorectal adenoma – n° (%)   23 (37.1)
Surgical treatment – n° (%) Right colectomy 16 (25.8)
Left colectomy 6 (9.7)
Sigmoidectomy 22 (35.5)
Anterior resection 9 (14.5)
Total colectomy 6 (9.7)
Abdominoperineal resection (Miles) 3 (4.8)
Chemotherapy – n° (%)c   35 (56.5)
Length of follow-up (months)d   49 (40–53)
  1. aExpressed as mean ± standard deviation
  2. bAll four cases correspond to loss of MLH1 protein expression
  3. cAll chemotherapeutic regimens included 5-fluorouracil, five of them in combination with oxaliplatin and two in combination with irinotecan
  4. dExpressed as median (range)